Following a full submission
AWMSG advice |
|||
Status: Recommended | |||
Isavuconazole (Cresemba®) is recommended as an option for use within NHS Wales for the treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list / contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
Medicine name | isavuconazole (Cresemba®) | ||
Formulation | 100 mg capsule; 200 mg powder for concentrate for solution for infusion | ||
Reference number | 2433 | ||
Indication | Treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate |
||
Company | Basilea Pharmaceuticals Ltd | ||
BNF chapter | Infections | ||
Submission type | Full | ||
Status | Recommended | ||
Advice number | 3616 | ||
NMG meeting date | 02/11/2016 | ||
AWMSG meeting date | 07/12/2016 | ||
Ratification by Welsh Government | 22/12/2016 | ||
Date of issue | 04/01/2017 | ||
Date of last review | September 2020 | ||
Commercial arrangement | WPAS |